이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

현직 환자에서 웨어러블 AR 안경을 이용한 안진 검사 평가

2026년 11월 11일 업데이트: Chang Gung Memorial Hospital

현훈 환자에서 웨어러블 증강 현실 안경을 사용하여 시행한 안진 검사의 평가: 무작위 등가성 연구

Background and Purpose:

Vertigo is common in emergency and outpatient settings, yet standard oculomotor testing usually requires dedicated equipment and exam rooms. This study evaluates whether nystagmus examinations performed with wearable augmented-reality (AR) glasses are equivalent to conventional examination-room testing for classifying central vs. peripheral vertigo. The investigators also assess diagnostic accuracy, patient tolerability, and the reliability of AR-based interpretation (test-retest and inter-rater).

Study Design:

Prospective, single-center, within-subject randomized equivalence study at Kaohsiung Chang Gung Memorial Hospital. Each participant completes both AR-based and conventional oculomotor testing in a randomized order during the same visit, separated by a 30-minute washout. The study uses an evaluator-blind approach: de-identified trajectories are reviewed offline by independent experts who are masked to test modality. A follow-up visit (~1 week) captures adverse events and patient experience.

Participants:

Adults (≥18 years) presenting with vertigo who can tolerate the AR headset and provide consent. Key exclusions include conditions that prevent reliable eye-tracking (e.g., corrected visual acuity <20/40), recent use of vestibular suppressants (within 24 hours), and other factors limiting cooperation or safety.

Interventions and Procedures:

The AR system records eye movements and presents standardized visual stimuli. Conventional testing follows current clinical standards (e.g., Frenzel/oculomotor exam). All recordings are stored securely for blinded review.

Outcomes:

Primary endpoint: Equivalence of diagnostic agreement (central vs. peripheral) between AR-based and conventional methods, quantified by Cohen's kappa (κ) with a predefined equivalence margin.

Secondary endpoints: (1) Diagnostic accuracy of the AR method in a clinically-indicated imaging subgroup (MRI preferred; CT as needed) using a sequential evaluation strategy; (2) Patient discomfort/tolerability using VAS and CSQ-VR, compared between modalities; (3) Test-retest reliability of AR-based classifications; (4) Inter-rater reliability between independent evaluators, with a third reader adjudicating discordant cases; (5) prespecified subgroup analyses by age, medical history, and vestibular function.

Sample Size and Duration:

Approximately 200 participants will be enrolled (target ~180 evaluable after ~10% attrition). Total study duration is ~2 years, including enrollment, follow-up, and analysis.

Risks and Benefits:

Both tests are non-invasive. Potential transient discomfort (e.g., eye strain or cybersickness) will be monitored. There may be no direct benefit to participants; however, results could support broader, more accessible, and standardized vertigo assessment.

Data Security and Privacy:

All data are de-identified, stored on secure platforms with role-based access and audit trails. Safety events are monitored and graded, and protocol deviations are handled per Good Clinical Practice.

연구 개요

상태

모병

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

200

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Ching-Nung Wu, MD, PhD
  • 전화번호: +886975369260
  • 이메일: taytay@cgmh.org.tw

연구 장소

    • Taiwan
      • Kaohsiung, Taiwan, 대만, 83301
        • 모병
        • Kaohsiung Chang Gung Memorial Hospital
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Adults ≥18 years with vertigo/dizziness suggestive of a central or peripheral vestibular disorder.
  • Able to complete both AR-based and conventional oculomotor testing during the same visit (with ~30-minute washout).
  • Provide written informed consent.
  • Adequate vision for eye-tracking and calibration (e.g., corrected visual acuity ≥20/40 in each eye).
  • Willing and able to return for the follow-up visit.

Exclusion Criteria:

  • Use of vestibular-suppressant medications within 24 hours prior to testing (e.g., benzodiazepines, antihistamines, anticholinergics).
  • Ocular conditions that would interfere with reliable eye tracking (e.g., corrected visual acuity <20/40, dense cataract, severe ptosis/strabismus, active ocular infection/inflammation).
  • History of photosensitive epilepsy or seizure disorder triggered by visual stimuli.
  • Severe motion sickness/cybersickness or inability to tolerate the AR headset.
  • Significant cognitive impairment or psychiatric condition precluding informed consent or protocol compliance.
  • Pregnant or breastfeeding (per investigator judgment and IRB policy).
  • Any other condition that, in the investigator's opinion, would make participation unsafe or confound study results.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 특수 증상
  • 할당: 무작위
  • 중재 모델: 크로스오버 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: AR-First Examination Sequence

AR-based examination first, then conventional examination

Intervention 1 - Wearable Augmented Reality Glasses for Nystagmus Examination Participants undergo a standardized nystagmus examination using wearable augmented reality (AR) glasses equipped with an integrated eye-tracking system. The AR-based system records real-time eye movements in both light and dark conditions, allowing for simultaneous examiner visualization and data storage. This method eliminates the need for traditional Frenzel goggles and provides automated signal quality assessment.

Intervention 2 - Conventional Nystagmus Examination Participants undergo a conventional clinical nystagmus examination performed by an otolaryngologist using standard Frenzel goggles under similar test conditions. Eye movements are visually assessed without integrated digital recording or automated signal analysis.

활성 비교기: Conventional-First Examination Sequence

Conventional examination first, then AR-based examination

Intervention 1 - Wearable Augmented Reality Glasses for Nystagmus Examination Participants undergo a standardized nystagmus examination using wearable augmented reality (AR) glasses equipped with an integrated eye-tracking system. The AR-based system records real-time eye movements in both light and dark conditions, allowing for simultaneous examiner visualization and data storage. This method eliminates the need for traditional Frenzel goggles and provides automated signal quality assessment.

Intervention 2 - Conventional Nystagmus Examination Participants undergo a conventional clinical nystagmus examination performed by an otolaryngologist using standard Frenzel goggles under similar test conditions. Eye movements are visually assessed without integrated digital recording or automated signal analysis.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Equivalence of Diagnostic Agreement (Central vs Peripheral) Between AR-Based and Conventional Examinations, Assessed by Cohen's Kappa
기간: Day 1 (immediately after completion of both AR-based and conventional examinations)

Cohen's Kappa (κ) will be used to evaluate diagnostic agreement between AR-based and conventional examinations. κ ranges from -1.0 to 1.0, where 1.0 indicates perfect agreement, 0 indicates chance-level agreement, and negative values indicate worse-than-chance agreement. Higher κ values represent better diagnostic consistency.

Day 1 (immediately after completion of both AR-based and conventional examinations)

2차 결과 측정

결과 측정
측정값 설명
기간
AR 기반 검사의 신경영상 대비 진단 정확도 (민감도, 특이도, 양성예측도, 음성예측도)
기간: 참가자가 임상적으로 필요한 MRI(선호됨) 또는 CT를 받는 경우, 1일차(기준 검사) 이후 30일 이내에
참가자가 임상적으로 필요한 MRI(선호됨) 또는 CT를 받는 경우, 1일차(기준 검사) 이후 30일 이내에
Test-Retest Reliability of AR-Based Examination (Cohen's Kappa)
기간: Day 1 - within 1 hour after completion of the initial AR-based examination

Test-retest reliability of AR-based examination will be assessed using Cohen's Kappa coefficient (κ). κ ranges from -1.0 to 1.0, where 1.0 indicates perfect agreement, 0 indicates chance-level agreement, and negative values indicate worse-than-chance agreement. Higher κ values indicate better reliability.

Day 1 - within 1 hour after completion of the initial AR-based examination
Patient Discomfort Measured by Visual Analog Scale (VAS)
기간: Day 1 - immediately after completion of AR-based and conventional examinations

Visual Analog Scale (VAS) will be used to assess patient-reported discomfort immediately after each test. The VAS ranges from 0 to 10, where 0 indicates no discomfort and 10 indicates the worst imaginable discomfort. Higher scores represent greater discomfort.

Day 1 - immediately after completion of AR-based and conventional examinations
Patient Discomfort Measured by Cybersickness Questionnaire for Virtual Reality (CSQ-VR)
기간: Day 1 - immediately after completion of AR-based and conventional examinations

Patient discomfort will also be measured using the Cybersickness Questionnaire for Virtual Reality (CSQ-VR). The CSQ-VR assesses cybersickness symptoms across multiple domains (e.g., nausea, oculomotor strain, disorientation). Scores range from 6 to 42, with higher scores indicating more severe discomfort.

Day 1 - immediately after completion of AR-based and conventional examinations
Inter-Rater Reliability of Diagnostic Interpretations (Cohen's Kappa; Fleiss' Kappa if applicable)
기간: Following Day 1 (baseline visit), blinded offline review of examination recordings prior to database lock

Inter-rater reliability of diagnostic interpretations will be assessed using Cohen's Kappa coefficient (κ) for two raters, and Fleiss' Kappa for three or more raters.

Cohen's Kappa (κ): Ranges from -1.0 to 1.0, where 1.0 indicates perfect agreement, 0 indicates agreement equivalent to chance, and negative values indicate worse-than-chance agreement. Higher values represent better inter-rater reliability.

Fleiss' Kappa: Ranges from -1.0 to 1.0, with the same interpretation as Cohen's Kappa.

Following Day 1 (baseline visit), blinded offline review of examination recordings prior to database lock

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 1월 1일

기본 완료 (추정된)

2028년 12월 31일

연구 완료 (추정된)

2029년 12월 31일

연구 등록 날짜

최초 제출

2025년 9월 16일

QC 기준을 충족하는 최초 제출

2025년 11월 18일

처음 게시됨 (실제)

2025년 11월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 11일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 202500606B0

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

De-identified individual participant data (IPD) underlying the primary and secondary outcome results will be made available to qualified researchers upon reasonable request. Data will be shared beginning 6 months after publication of the main results and for up to 5 years thereafter. Requests should be directed to the principal investigator via institutional email and must include a methodologically sound proposal and a signed data use agreement.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .